Vertex Pharmaceuticals Incorporated logo

Vertex Pharmaceuticals Incorporated VRTX

$ 484.69 0.91%

Annual report 2024
added 02-13-2025

report update icon

Country

usaUSA

IPO year

1991

Industry

Biotechnology

Stock Exchange

NASDAQ GLOBALSPB

CEO

Dr. Jeffrey Leiden

Employees in the company

3 000

Shares

258 M

Market Cap[1]

$ 125 B

EBITDA (LTM)

$ 4.35 B

P/E (LTM)

-

P/S (LTM)

-

EPS (LTM)

-

Vertex Pharmaceuticals is an American biotechnology company specializing in the development of drugs for the treatment of rare diseases. The company was founded in 1989 in Cambridge, Massachusetts.

Vertex Pharmaceuticals' main area of focus is the research and development of new drugs for the treatment of genetic diseases such as cystic fibrosis, Berger's syndrome, thalassemia, and others.

One of the company's most well-known products is the drug Kalydeco, which is used to treat cystic fibrosis. In addition, Vertex Pharmaceuticals is working on the development of new drugs for the treatment of cancer, Parkinson's disease, and other conditions.

The company actively invests in scientific research and the development of new drugs. Vertex Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.

Vertex Pharmaceuticals has a wide network of distributors and partners around the world, which allows it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.

Other stocks of industry "Biotechnology"

Issuer Price % 24h Market Cap Exchange Country
CureVac N.V. CureVac N.V.
CVAC
$ 3.33 1.45 % $ 619 M Nasdaq Global Market germanyGermany
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M Nasdaq Global Select Market usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 14.47 0.56 % $ 371 M Nasdaq Global Market usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M Nasdaq Capital Market usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M Nasdaq Global Select Market britainBritain
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 5.26 -2.23 % $ 221 M Nasdaq Global Market usaUSA
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M Nasdaq Capital Market usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M Nasdaq Capital Market usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
$ 0.29 -18.52 % $ 27.3 M Nasdaq Global Select Market britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M Nasdaq Capital Market usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M NYSE canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M Nasdaq Global Market usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
$ 2.13 -2.74 % $ 78.5 M Nasdaq Capital Market israelIsrael
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B Nasdaq Global Select Market usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
$ 5.72 5.93 % $ 314 M Nasdaq Capital Market canadaCanada
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M Nasdaq Global Select Market usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.15 -1.51 % $ 35.3 M Nasdaq Global Market usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M Nasdaq Global Select Market usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M Nasdaq Global Market israelIsrael
Kiromic BioPharma Kiromic BioPharma
KRBP
$ 3.15 6.61 % $ 3.08 M Nasdaq Global Select Market usaUSA

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.